PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
PALVELLA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$122.96+2.66 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
PALVELLA THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q3 20 | Q2 20 | Q1 20 | Q4 19 | Q3 19 | Q2 19 | Q1 19 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Customer revenue | $2.58M | $10.93M | $8.89M | $16.53M | $3.59M | $4.72M | $7.23M | 87.7% | -28.2% |
| Collaboration revenue | $361.00K | $316.00K | $4.38M | $743.00K | $11.54M | $609.00K | $1.32M | 12.3% | -96.9% |
By region
From the segment and revenue-disaggregation notes of Palvella Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.